Jyong Biotech

Jyong Biotech FCF per Share

The Free Cash Flow per Share of Jyong Biotech (MENS) as of Nov 20, 2026 is -0.04 USD. In the previous year, Free Cash Flow per Share was -50.61 USD — a change of -99.92% (higher).

FCF per Share

-0.04USD

YoY

-99.92%

Last updated:

Free Cash Flow per Share of Jyong Biotech is 2025 -0.04 USD. Free Cash Flow per Share of Jyong Biotech was 2024 -50.61 USD. It decreases by -99.92% higher compared to the previous year.

The Jyong Biotech FCF per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF per Share
Date
FCF per Share
Jan 1, 2020
-0.02 USD
Jan 1, 2021
-0.03 USD
Jan 1, 2022
-44.93 USD
Jan 1, 2023
-36.33 USD
Jan 1, 2024
-50.61 USD
Jan 1, 2025
-0.04 USD
The Jyong Biotech FCF per Share history
YEARFCF per ShareYoY
-0.04USD-99.92%
-50.61USD+39.33%
-36.33USD-19.15%
-44.93USD+157,152.83%
-0.03USD+80.51%
-0.02USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Jyong Biotech Stock analysis

What does Jyong Biotech do? Jyong Biotech Ltd. develops and commercializes plant-derived biotechnology products, focusing on urinary system diseases. The company's primary product is MCS-2, a botanical drug candidate for benign prostate hyperplasia/lower urinary tract symptoms (BPH/LUTS), and PCP, a clinical-stage botanical drug candidate for prostate cancer prevention. These products target markets in the United States, European Union, and Asia. The firm generates revenue through the development and eventual commercialization of these innovative botanical drug candidates, with MCS-2 and PCP representing key stages in its pipeline. Jyong Biotech's business model centers on advancing its botanical drug candidates through clinical and preclinical stages. The company employs 29 full-time employees to manage research, development, and commercialization efforts. Its focus on plant-derived treatments for urinary system diseases positions it to serve patients and healthcare providers in the U.S., EU, and Asian markets. The firm's revenue streams will primarily come from the successful development and sale of MCS-2 and PCP once they reach commercialization. The company's product portfolio includes MCS-2, PCP, and other preclinical-stage botanical drug candidates. These products are developed for specific medical conditions, with MCS-2 targeting BPH/LUTS and PCP targeting prostate cancer prevention. The firm's strategy involves leveraging its botanical drug development expertise to enter key global markets. Revenue will be generated once these products are approved and sold in the U.S., EU, and Asia. Jyong Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Jyong Biotech stock

Free Cash Flow per Share of Jyong Biotech is -0.04 USD in 2025.

Free Cash Flow per Share of Jyong Biotech changed from -50.61 USD to -0.04 USD, representing a -99.92% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share Jyong Biotech since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Jyong Biotech

All Key Metrics — Jyong Biotech